Pfizer awarded funding to members of the CTSR to study atopic dermatitis

We are pleased to announce that Professor Fernandez-Penas (principal investigator) and Dr Ali Azimi were successful in securing AUD $229000.00 from Pfizer Pharmaceuticals to study clinical samples of patients with atopic dermatitis (AD) for the identification of protein biomarkers and molecular pathways that correlate with different ethnicities.

The findings of this novel approach will aid in our understanding of the molecular mechanisms behind the development and progression of AD in each study group and will facilitate the development of new targeted therapies.